ChemComm
Communication
Scheme 5 [3+2] Cycloaddition of N-carbamoyl azide with phenyl
acetylene catalyzed by [Tpa*Cu]PF6. Reaction conditions: azide (1 mmol),
alkyne (1.2 mmol), DCE (1 mL), 40 1C, 24 h. Isolated yields based on azide
(average of two runs).
Moreover, the process was compatible with the presence
of a sulphur-containing heterocycle on the alkyne (5). Alkyl-
substituted acetylenes were also tested as substrates, but the
reactions had to be carried out at higher temperatures (60 1C) to
reach good conversions. Once more, the products were
obtained in high yields regarding the nature of the alkyl group
(6–9). As commonly observed in CuAAC reactions, internal
alkynes were totally inert under these conditions.16
To further explore the scope of the reaction, different
N-carbamoyl azide substrates were subjected to this [3+2]
cycloaddition reaction with phenyl acetylene (Scheme 5). In
all cases, the corresponding N-carbamoyl 1,2,3-triazoles were
formed under the reaction conditions, although yields were
lower than that found for the model substrate.
Scheme 6 Mechanistic proposal for the formation of oxazoles (a) and
triazoles (b) through the reaction of carbonyl azides and terminal alkynes
catalyzed by [Tpa*Cu]PF6.
CuAAC reaction with N-carbamoyl azides as substrates. This
mild protocol represents a powerful alternative to existing
procedures for the preparation of this class of bioactive com-
pounds from readily available starting material. Further inves-
tigations to extend the scope of this transformation are ongoing
in our laboratory.
We thank MINECO (CTQ2011-28942-CO2-01, CTQ2011-27033)
´
and Junta de Andalucıa (Proyecto P07-FQM-02745, P10-FQM-06292).
N-Carbamoyl triazoles have proven to be potent serine hydro-
lase inhibitors.13 The reported method for the synthesis of these
compounds consists of a two step procedure which involves the
preparation of 1H-1,2,3-triazole via CuAAC and its subsequent
coupling with a N-aminecarbonyl chloride. Mixtures of N1- and
N2-carbamoylated regioisomers are obtained. Instead, with our
synthetic approach only the N1-regioisomer is achieved in good
yields in a one-step catalytic procedure.13a In addition, the
precatalyst [Tpa*Cu]PF6 is easy to make17 and sufficiently stable
to moisture and air to be weighted on a benchtop.
Scheme 6 displays a general mechanistic explanation for the
reaction of several azides and alkynes in the presence of this
type of copper catalysts. Two possible pathways can be invoked
to explain the formation of 1,2,3-triazoles from N-sulfonyl- or
N-carbamoyl azides or that of oxazoles from N-carbonyl azides. In
the latter, the metal centre prefers the azide group to form a nitrene
intermediate, which reacts further with the alkyne12b rendering the
formation of the oxazole (Scheme 6, cycle A). On the other hand,
the N-sulfonyl- or N-carbamoyl azides do not lead to nitrene
intermediates, since the formation of copper acetylides must be
favored. From here, interaction with the azide and subsequent
formation of the triazolyl–cuprate could explain the formation of
the triazole derivatives (Scheme 6, cycle B). The intermediacy of two
copper centres for the [3+2] reaction to occur has been previously
proposed by several groups.18 In our case, we cannot rule out the
assistance of a second molecule of the catalyst in the process.
In summary, we have discovered a Cu(I) precursor that for
the first time allows the formation of N-carbonyl triazoles by
EH thanks MEC for a research grant.
Notes and references
1 (a) L. L. Brockunier, E. R. Parmee, H. O. Ok, M. R. Candelore,
M. A. Cascieri, L. F. Colwell Jr., L. Deng, G. J. Hom, W. P. Feeney,
M. J. Forrest, G. J. Hom, D. E. MacIntyre, L. Tota, M. J. Wyvratt, M. H.
Fisher and A. E. Weber, Bioorg. Med. Chem. Lett., 2000, 10, 2111;
(b) B. S. Holla, M. Mahalinga, M. S. Karthikeyan, B. Poojary,
P. M. Akberali and N. S. Kumari, Eur. J. Med. Chem., 2005, 40, 1173;
(c) V. Pande and J. M. Ramos, Bioorg. Med. Chem. Lett., 2005, 15, 5129;
(d) M. Whitting, J. Muldoon, Y.-C. Lin, S. M. Silverman, W. Lindstrom,
A. J. Olson, H. C. Kolb, M. G. Finn, K. B. Sharpless, J. H. Elder and
V. V. Fokin, Angew. Chem., Int. Ed., 2006, 45, 1435; (e) M. Aufort,
J. Herscovici, P. Bouhours, N. Moreau and C. Girard, Bioorg. Med.
Chem. Lett., 2008, 18, 1195; ( f ) S. R. Patpi, L. Pulipati, P. Yogeeswari,
D. Sriram, N. Jain, B. Sridhar, R. Murthy, T. A. Devi, S. V. Kalivendi and
S. Kantevari, J. Med. Chem., 2012, 55, 3911.
2 (a) R. Huisgen, Angew. Chem., Int. Ed. Engl., 1963, 2, 565; (b) R. Huisgen,
Angew. Chem., Int. Ed. Engl., 1963, 2, 633; (c) R. Huisgen, Pure Appl. Chem.,
1989, 61, 613.
3 C. W. Tornøe, C. Christensen and M. P. Meldal, J. Org. Chem., 2002,
67, 3057.
4 V. V. Rostovtsev, L. G. Green, V. V. Fokin and K. B. Sharpless,
Angew. Chem., Int. Ed., 2002, 41, 2596.
5 For general reviews on CuAAC reactions, see: (a) V. D. Bock,
H. Hiemstra and J. H. van Maarseveen, Eur. J. Org. Chem., 2006,
51; (b) J. E. Moses and A. D. Moorhouse, Chem. Soc. Rev., 2007,
36, 1249; (c) M. P. Meldal and C. W. Tornøe, Chem. Rev., 2008,
108, 2952; (d) J. E. Hein and V. V. Fokin, Chem. Soc. Rev., 2010,
´
´
39, 1302; (e) S. Dıez-Gonzalez, Catal. Sci. Technol., 2011, 1, 166.
6 For applications in drug discovery see for example: (a) H. C. Kolb
and K. B. Sharpless, Drug Discovery Today, 2003, 8, 1128; (b) J.-F. Lutz
and Z. Zarafshani, Adv. Drug Delivery Rev., 2008, 60, 958; (c) G. C.
Tron, T. Pirali, R. A. Billington, P. L. Caninico, G. Sorba and
A. A. Genazzani, Med. Res. Rev., 2008, 28, 278; (d) A. D. Moorhouse
8980 | Chem. Commun., 2014, 50, 8978--8981
This journal is ©The Royal Society of Chemistry 2014